Pharma Giants Eye Massive Merger as Amgen Joins Data Breach Roster
A potential megamerger between AstraZeneca and Bristol Myers Squibb has industry eyes fixed on a deal that could value the pharma giants at roughly $400 billion, making it one of the largest pharma tie-ups in history. However, neither company has confirmed the report, and analysts question why AstraZeneca would make such a move given its rising stock under CEO Pascal Soriot.
Amgen is the latest health company to announce a data breach, joining Novo Nordisk, Abbott, Medtronic, and others in recent weeks. Amgen claims no impact on products, manufacturing operations, financial reporting systems, or patient needs has been found.
A $450 million settlement agreement between Sandoz and 43 U.S. states does not affect the company's full-year 2026 guidance or mid-term outlook.